Catalyst Pharmaceuticals (CPRX) Net Income towards Common Stockholders (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Net Income towards Common Stockholders data on file, last reported at $63.7 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 12.33% year-over-year to $63.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.0 million (up 17.04% YoY) and the FY2025 annual result came in at $224.0 million, up 36.66% from the prior year.
• Net Income towards Common Stockholders grew to $63.7 million in Q1 2026, from $62.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $63.7 million in Q1 2026 to a low of -$30.8 million in Q3 2023.
• A 5-year average of $34.6 million and a median of $37.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 235.24% — and 2024, when it soared 242.65%.
• Tracing CPRX's Net Income towards Common Stockholders over 5 years: stood at $25.5 million in 2022, then plunged by 33.1% to $17.0 million in 2023, then surged by 228.28% to $55.9 million in 2024, then grew by 11.46% to $62.3 million in 2025, then grew by 2.22% to $63.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $63.7 million (Q1 2026), $62.3 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.